Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ: TSVT )

12.35 +0.57 (+4.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 623,193
Open 11.88
Bid (Size) 11.50 (1)
Ask (Size) 13.00 (1)
Prev. Close 11.78
Today's Range 11.30 - 12.44
52wk Range 10.57 - 44.34
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
Upgrades 
Via Benzinga

Performance

YTD
-53.78%
-53.78%
1 Month
-19.81%
-19.81%
3 Month
-14.36%
-14.36%
6 Month
-62.97%
-62.97%
1 Year
-63.27%
-63.27%

More News

Read More
2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in CG Horizons in Oncology Virtual Conference
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Secures $170 Million in Private Placement Equity Financing
From 2seventy bio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
2seventy bio Announces Key Management Appointments
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in Upcoming Healthcare Conferences
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
Via Benzinga
2seventy bio Shares Key Milestones and Business Updates for 2022
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
3 Best Performing Healthcare IPOs in 2021
Via Talk Markets
2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting
From 2seventy bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
41 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
2seventy bio to Present at the 5th Annual Cowen IO Next Summit
From 2seventy bio, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.